Low antituberculosis drug concentrations in patients with AIDS

Annals of Pharmacotherapy

Volumn 30, Issue 9, 1996, Pages 919-925

  Peloquin, Charles A ^a,b   Nitta, Annette T ^c   Burman, William J ^d   Brudney, Karen F ^e   Miranda Massari, Jorge R ^f   McGuinness, Margaret E ^g   Berning, Shaun E ^h,i   Gerena, Gail T ^j  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Los Angeles County Tuberculosis Control Program   (United States)

^d DENVER PUBLIC HEALTH   (United States)

^e Department of Orthopaedic Surgery   (United States)

^f UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^h Department of Pediatrics   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

^j BELLEVUE HOSPITAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; FLUCONAZOLE; ISONIAZID; OFLOXACIN; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; TREATMENT PLANNING; TUBERCULOSIS;

EID: 0029841198     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000901     Document Type: Article

References (24)

1. Berning SE, Huitt GA, Iseman MD, Peloquin CA. Malabsorption of anti-tuberculosis medications by a patient with AIDS (letter). N Engl J Med 1992;327:1817-8.
2. Peloquin CA, MacPhee AA, Berning SE. Malabsorption of antimycobacterial medications (letter). N Engl J Med 1993;329:1122-3.
3. Gordon SM, Horsburgh CR, Peloquin CA, Havlik JA, Metchock B, Heifets L, et al. Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease. J Infect Dis 1993;168:1559-62.
4. Peloquin CA. Antituberculosis drugs: pharmacokinetics. In Heifets L, ed. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press, 1991:59-88.
5. Peloquin CA. Pharmacology of the antimycobacterial drugs. Med Clin North Am 1993;77:1253-62.
6. Peloquin CA. Therapeutic drug monitoring: principles and application in mycobacterial infections. Drug Ther 1992;22:31-6.
7. Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney B, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994;330:1179-84.
8. Jindani A, Aner VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980;121:939-49.
9. Jenne JW, Beggs WH. Correlation of in vitro and in vivo kinetics with clinical use of isoniazid, ethambutol, and rifampin. Am Rev Respir Dis 1973;107:1013-21.
10. Heifets LB. Introduction: drug susceptibility and the clinical outcome of chemotherapy. In: Heifets LB, ed. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press, 1991:1-11.
11. Heifets LB. Antituberculosis drugs: antimicrobial activity in vitro. In: Heifets LB, ed. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press, 1991:13-58.
12. Comstock GW, Hammes LM, Pio A. Isoniazid prophylaxis in Alaskan boarding schools. A comparison of two doses. Am Rev Respir Dis 1969; 100:773-9.
13. Doster B, Murray FJ, Newman R, Woolpert SF. Ethambutol in the initial treatment of pulmonary tuberculosis. Am Rev Respir Dis 1973;107:177-90.
14. Long MW, Snider DE Jr, Farer LS. U.S. Public Health Service cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979;119:879-94.
15. Turner M, McGowan C, Nardell E, Haskal R. Serum drug levels in tuberculosis patients (abstract). Am J Respir Crit Care Med 1994;149(4, part 2):A527.
16. Patel KB, Belmonte R, Crowe HM. Drug malabsorption and resistant tuberculosis in HIV-infected patients (letter). N Engl J Med 1995;332:336-7.
17. Peloquin CA, James GT, Craig LD, Kim M, McCarthy EA, Iklé DN, et al. Pharmacokinetic evaluation of aconiazide, a potentially less toxic isoniazid pro-drug. Pharmacotherapy 1994;14:415-23.
18. Jelliffe RW, Schumitzky A, Guilder MV, Liu M, Hu L, Maire P, et al. Individualized drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit 1993;15:380-93.
19. D'Argenio DZ. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 1981;9:739-56.
20. Trapnell CB, Narang PK, Li R, Lewis R, Colborn D, Lavelle J. Fluconazole increases rifabutin absorption in HIV (+) patients on stable zidovudine therapy (abstract). Ninth International Conference on AIDS/Fourth STD World Congress, Berlin, Germany, June 1993.
21. Coker RJ, Tomlinson DR, Parkin J, Harris JR, Pinching AJ. Interaction between fluconazole and rifampicin (letter). Br Med J 1990;301:818.
22. Lazar JD, Wilner KD. Drug interactions with fluconazole. Rev Infect Dis 1990;12(suppl3):S327-33.
23. Fox W. Drug combinations and the bioavailability of rifampicin. Tubercle 1990;71:241-5.
24. Jain A, Mehta VL, Kulshrestha S. Effect of pyrazinamide on rifampicin kinetics in patients with tuberculosis. Tuber Lung Dis 1993;74:87-90.